Tsuji D, et al. - Researchers investigated the risk factors related to chemotherapy-induced nausea and vomiting (CINV) development in patients receiving cisplatin. In addition, they compared CINV risk factors between palonosetron and granisetron use. Evaluating 825 patients in a phase III trial receiving palonosetron with granisetron, they identified sex, age, cisplatin dose, and granisetron use as significant and independent factors affecting CINV development in the overall phase. Similarly, in both treatment groups, sex and age were identified to be risk factors for CINV. As per Kaplan–Meier curves classified by each treatment group, there appeared no significant difference between the groups among patients without any risk factors for CINV. Conversely, patients receiving palonosetron had higher complete response rates among patients with at least one risk factor. Hence they suggest preferring palonosetron for patients with at least one risk factor.